Evidence map›Paper›PMID 24772236›Full record

ReviewWorld journal of stem cells2014

Enhancing the efficacy of mesenchymal stem cell therapy.

Michalis Mastri, Huey Lin, Techung Lee

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of stem cells, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed.

  1. Trial
  2. Review
  3. NINJ1 impairs the anti-inflammatory function of hUC-MSCs with synergistic IFN-γ and TNF-α stimulation.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michalis MastriMichalis Mastri, Huey Lin, Techung Lee, Department of Biochemistry, University at Buffalo, Buffalo, NY 14214, United States.
Huey LinMichalis Mastri, Huey Lin, Techung Lee, Department of Biochemistry, University at Buffalo, Buffalo, NY 14214, United States.
Techung LeeMichalis Mastri, Huey Lin, Techung Lee, Department of Biochemistry, University at Buffalo, Buffalo, NY 14214, United States.

Funding

Mesenchymal Stem Cell Therapeutics in Hibernating MyocardiumR01HL084590 · NHLBI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LEE, TECHUNG · 2006 to 2010
$1.9M
NHLBI NIH HHS R01 HL084590
6 · The paper itself

Abstract

Mesenchymal stem cell (MSC) therapy is entering a challenging phase after completion of many preclinical and clinical trials. Among the major hurdles encountered in MSC therapy are inconsistent stem cell potency, poor cell engraftment and survival, and age/disease-related host tissue impairment. The recognition that MSCs primarily mediate therapeutic benefits through paracrine mechanisms independent of cell differentiation provides a promising framework for enhancing stem cell potency and therapeutic benefits. Several MSC priming approaches are highlighted, which will likely allow us to harness the full potential of adult stem cells for their future routine clinical use.

Indexed as

Clinical trialMesenchymal stem cellParacrineTherapy

Identifiers

PMID24772236
PMCPMC3999784

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.